** Shares of OPKO Health OPK.O up 4.7% to $1.57 premarket
** Late-Thursday, ModeX Therapeutics Inc, an OPK subsidiary,
was awarded a contract from the Biomedical Advanced Research and
Development Authority (BARDA)
** Contract to advance a platform and specific candidates
designed to address a range of public health threats in viral
infectious diseases
** The contract includes an initial $59 mln funding for a
multi-specific antibody against SARS-CoV-2
** Additional funding of up to $109 mln may be available
upon achieving particular milestones to develop multispecific
antibodies targeting other viral pathogens such as influenza
** Up to last close, OPK stock up 20.4% so far this year
(Reporting by Pratik Jain in Bengaluru)
((Pratik.Jain@thomsonreuters.com;))